20.500.12556/DiRROS-24132 Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients Background: Psoriasis is associated with increased cardiovascular risk, possibly mediated by inflammation-induced hemostatic dysregulation and hypercoagulability. However, these changes are often difficult to detect with conventional markers. Objectives: To assess hypercoagulability in patients with psoriasis using the Overall Hemostatic Potential (OHP) test, a global integrative test for coagulation and fibrinolysis. Methods: We studied 80 psoriasis patients (54 men, 26 women, aged 30– 45 years) receiving effective topical or systemic treatments (methotrexate, adalimumab, secukinumab or guselkumab) and compared them with 20 healthy controls. We measured OHP, its components — overall coagulation potential (OCP) and overall fibrinolytic potential (OFP) and selected hemostatic markers (platelet count, mean platelet volume, platelet-to-lymphocyte ratio, P-selectin, D-dimer and fibrinogen). Results: Psoriasis patients had significantly higher OHP levels, primarily due to decreased OFP, while OCP levels were comparable to the control group — indicating a hypercoagulable state due to impaired fibrinolysis. Other conventional hemostatic markers showed no significant differences. OHP and OFP correlated with residual inflammatory activity, BMI, waist circumference, visceral adiposity and fibrinogen levels, suggesting a relationship between subclinical inflammation, metabolic parameters and hemostatic imbalance. Conclusion: The OHP test reveals a hypercoagulable state in psoriasis patients even in the absence of abnormal standard coagulation markers. OHP could be a practical and sensitive tool to stratify cardiovascular risk in psoriasis, especially in patients with concomitant metabolic disease or persistent inflammation. psoriasis hypercoagulability overall hemostatic potential OHP fibrinolysis obesity true false true Angleški jezik Ni določen Neznano 2025-11-17 13:04:46 2025-11-17 13:04:46 2025-11-18 03:43:32 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 22. 8. 2025; str. 1-9 [article no.] 1611827 Vol. 12 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616.517:616.1 2296-858X 10.3389/fmed.2025.1611827 246339587 RAZ_Merzel_Sabovic_Eva_Klara_2025.pdf RAZ_Merzel_Sabovic_Eva_Klara_2025.pdf 1 0D8965C99241A8DE496468CA1DB3731B 56be3e0efe578eb86a8594b06d81ba4677e5d96c3c0659485f63d996cbdc7da7 cef81e97-c3ad-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=35909 https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1611827/full 0 da206c69-c3ad-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=35910 Univerzitetni klinični center Ljubljana 0 0 0